Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer.
Bladder Cancer
; 9(2): 159-166, 2023.
Article
em En
| MEDLINE
| ID: mdl-38993293
ABSTRACT
BACKGROUND:
Devices that increase the penetrance of intravesical chemotherapeutics are emerging as alternatives to classical Bacillus Calmette Guérin (BCG) treatment.OBJECTIVE:
To compare the efficacy of mitomycin C applied with the electromotive drug delivery device (MMC-EMDA) versus BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) without carcinoma in situ (CIS).METHODS:
Prospective non-randomized study in which 47 patients received MMC-EMDA (40âmg of MMC diluted in 50âmg of distilled water at 20âmA for 30âmin. Regimen of 6 weekly and then 6 monthly instillations) and 48 patients received BCG (50âmg of OncoCITE® diluted in 50âml of normal saline for 60âmin. Regimen of 6 weekly instillations and then 3 weekly instillations at months 3, 6 and 12). The primary endpoint was the recurrence-free rate (RFR) at 24 months. Secondary endpoints were time to recurrence and progression-free rate (PFR) at 24 months follow-up.RESULTS:
Baseline patient assessment and mean follow-up time were similar in both groups (MMC-EMDA group 26.4 months; BCG group 28.4 months (pâ=â0.44)). The RFR at 24 months was 80.9% for the MMC-EMDA group and 77.1% for the BCG group (pâ=â0.969). The mean time to recurrence was 12.5 months in the MMC-EMDA group and 14 months in the BCG group (pâ=â0.681). At 24 months, PFR was 97.9% in the MMC-EMDA group and 93.8% in the BCG group (pâ=â0.419).CONCLUSIONS:
No differences were found between MMC-EMDA and BCG treatments in patients with high-risk and intermediate-risk NMIBC without CIS.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Bladder Cancer
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Espanha